MedTrace Logo

The Effects of Ramipril on Clinical Symptoms in Patients With Peripheral Arterial Disease

NCT00168467 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2009-01-29

No results posted yet for this study

Summary

One important clinical challenge in older individuals is maintaining mobility in the absence of pain. Peripheral arterial disease affects up to 12% of adults over 50 and impairs quality of life due to intermittent claudication causing pain and limiting mobility.

Conventional therapies have only modest effect in improving symptoms. The investigators hypothesise that angiotensin converting enzyme inhibition (with ramipril), which causes arterial vasodilation, also improves clinical symptoms in patients with peripheral arterial disease.

Conditions

  • Peripheral Arterial Disease

Interventions

DRUG

Ramipril

Sponsors & Collaborators

  • Baker Heart Research Institute

    lead OTHER

Principal Investigators

  • Bronwyn A Kingwell, PhD · Baker Heart Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00168467 on ClinicalTrials.gov